Τόμος 23 (2005) – Τεύχος 2 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 23 (2005) – Issue 2 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Βασίλης Α. Κόκκας, Αντώνης Γούλας, Ανδρέας Κόκκας

Εργαστήριο Φαρμακολογίας, Τμήμα Ιατρικής, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

B. Kokkas, A. Goulas, A. Kokkas

Department of Pharmacology, Medical School, Aristotle University of Thessaloniki, Greece

2. Κόκκας Β.: Θέματα Μοριακής Φαρμακολογίας. University Studio Press, Θεσσαλονίκη, 1999

3. Henderson B., Blake S.: Therapeutic potential of cytokine manipulation. Trends Pharmacol. Sci. 13: 145-152 (1992)

4. Haynes B., Fauci A.: Introduction to the immune system. In: (Braunwald E. et al., eds) Harrison’s. Principles of Internal Medicine. P. 1805, McGraw-Hill Med. Publ. Div., New York, (2001)

5. Mann D.: Cytokines as mediators of disease progression in the failing heart. In: (Hosenpud J., Greenberg B., eds) Congestive Heart Failure. Lippicott Williams and Wilkins, Philadelphia, 2000

6. Dinarello C.: Biological basis for interleukin-1 in disease. Blood 87: 2095-2147, 1996

7. Ι. Marnett L. and Kalgutkar A.: Cyclooxygenase 2 inhibi­tors. Discovery selectivity and the future. Trends Pharma­col. Sci. 20: 465-469 (1999)

8. Baggiolini M., Loetscher P., Thelen M.: Theodor Kocher Institute, University of Bern, Switzerland. Trends pharmacol. Sci. 21: attached paper, (2000)

9. Wells T., Power Ch., Proudfoot A.: Definition, function and pathophysiological significance of chemokinine re­ceptors. Trends Pharmacol.Sci. 22: 146-152 (2001)

10. Murphy P.: Chemokinine receptors. glucocorticoids and pathological significance. National Istitutes of Health, Be­thesda. MD USA, Trends Pharmacol. Sci. 17: attached paper, (1996)

11. Cho M.L., Kim W.U., Min S.Y.: Cyclosporine differen­tially regulates interleukin-10, interleukin-15 and tumor necrosis factor α production by rheumatoid synoviocytes. Arthritis Rheum. 46: 42-51 (2002)

12. Lee S.L., Lee S.: Toll like receptors and inflammation in the CNS. In Current Drugs Targets-inflammation and Allergy. Vol, No 2: 181-191 (2002), Internet-Medline

13. Boehncke W., Schon M.: Interfering with leukocyte rolling. A promising therapeutic approach in inflammatory skin disorders. Trends Pharmacol. Sci. 24: 49-52 (2003)

14. Θεοδώρου Ι.: NF-kB οδός σηματοδότησης και Τ-κατευθυνόμενες θεραπείες. Πρακτικά Επιστ. Ημερίδας Θεραπευτικές στρατηγικές που στοχεύουν στο Τ-λεμφοκύτταρο. Σελ. 20 Θεσσαλονίκη 1-11-2003

15. Emery J., Ohlstein E., Jaye M.: Therapeutic modula­tion of transcription factor activity. Trends Pharmacol.Sci. 22: 233-240 (2001)

16. Eder J.: Tumour necrosis factor a and interleukin 1 signalling. Trends Pharmacol.Sci. 18: 319-322 (1997)

17. Schimmer B., Parker K.: Adrenocorticotropic hormone. In: (Hardman J., Limbird L., eds) Goodman and Gilmans. The Pharmacol­ogical Basis of Therapeutics. P. 1649 McGraw-Hill Med. Publ. Co., New York, 2001

18. Κουντουράς Ι.: Η κυκλοσπορίνη και φλεγμονώδη νοσήματα του εντέρου. Πρακτικά Επιστ. Ημερίδας Θεραπευ-τικές στρατηγικές που στοχεύουν στο Τ-λεμφοκύτταρο. Σελ. 12-17, Θεσσαλονίκη 1-11-2203

19. Vandenbroeck K., Goris A.: Cytokine gene polymor­phisms in multifactorial diseases: gateways to novel tar­gets for immunotherapy. Trends Pharmacol.Sci. 24: 284-289 (2003)

20. Saba R., Guler M., Inan D.: The effect of granulocyte-stimulating factor in the treatment of Escherichia coli peri­tonitis with or without ceftriaxone in a nonneutropenic rat model. Surg. Today 33: 504-508 (2003)

21. Hubel K., Dale D., Liles W.: Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases. Current status of granulocyte col­ony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage-stimulating factor and interferon-gamma. J. Infect. Dis. 185: 1490-1501 (2002)

22. Wunderink R., Leeper K., Schein R., Nelson S.: Filigastrin in patients with pneumonia and severe sepsis or septic shock. Chest 119: 523-529 (2001)

23. Arslan E., Yavuz M., Dalay C.: The relationship be­tween tumor necrosis factor (TNF)-alpha and survival following granulocyte-colony stimulating factor (G-CSF) administration in burn sepsis. Burns 26: 521-524 (2000)

24. Dibbert B., Weber M., Nikolaizik W.: Cytokine-medi­ated Bax definciency and consequent delayed neutrophil apoptosis. A general mechanism to accumulate effector cells in inflammation. Proc. Natl. Acad. Sci. 96: 13330-13335 (1999)

25. Hillman R.: Hematopoitic agents. In: (Hardman J., Limbird L., eds) Goodman and Gilmans. The Pharmacol­ogical Basis of Therapeutics. Pp. 1487-1517, McGraw-Hill Med. Publ. Co., New York, 2001

26. Krensky A., Strom T., Bluestone J.: Immunomodula­tors. In: (Hardman J., Limbird L., eds) Goodman and Gil­mans. The Pharmacological Basis of Therapeutics. Pp. 1463-1487, McGraw-Hill Med. Publ. Co., New York,

27. Devalaraja M., Richmond A.: Multiple chemotactic factors. Fine control or redundancy? Trends Pharmacol. Sci. 20: 151-157 (1999)

28. Snyder S., Sabatini D., Lai M., Steiner J.: Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 19: 21-25 (1998)

29. Chen F., Demers L., Shi X.: Upstream signal tranduc­tion of NF-kB activation. In: Current Drugs Targets-inflam­mation and Allergy. Vol, No 2: 137-149 (2002), Internet-Medline

30. Wiegers G., Reul M.: Induction of cytokine receptors by glucocorticoids and pathological significance. Trends Pharmacol. Sci. 19: 317-321 (1998)

31. Buckibinder L., Robinson R.: The glucorticoid receptor. Molecular mechanisms and new therapeutic opportunities. In: Current Drugs Targets-inflammation and Allergy. Vol, No 2: 127-136 (2002), Internet-Medline

32. Lever R.: iNOS in arthritis-inducible or innocent. Trends Pharmacol. Sci. 22: 220-221 (2001)